Clinical Diagnostics And Drug Development Articles & Analysis
13 articles found
Recombinant protein drugs refer to protein products that originate from animals and plants and are developed through biotechnology research. These protein drugs exhibit certain biological activity and can prevent, diagnose, and treat diseases in humans, animals, and plants. Compared with small molecular drugs, recombinant protein drugs offer advantages such as high activity, high specificity, and ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹?³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and ...
They have the advantages of small size, high stability, and good penetration, and therefore have a wide range of application prospects in the fields of clinical treatment, diagnostic reagent development, etc.Characteristics of NanobodiesThe size of nanobodies usually ranges between 10-15kDa, which is only 1/10 of the size of regular antibodies. ...
Therefore, nanobodies have shown good control effects in disease diagnosis, cancer and infectious diseases.What are Nanobody-Drug Conjugates (NDCs)The development concept of nanobody-drug conjugates (NDCs) is similar to that of antibody drug conjugates (ADC), that is, the antibody in ADC is replaced by a nanobody with higher ...
Rare diseases, also known as orphan diseases, are a diverse group of disorders that affect a small percentage of the population. Due to their low prevalence and limited understanding, treating and finding cures for these conditions present significant challenges. However, preclinical animal models have emerged as invaluable resources for advancing research and unraveling the mysteries surrounding ...
Effective and Efficient Drug Development Challenge Increased Cost, Risk, and Competition in the Drug Development Processes Dr. Luis Rojas, the Executive Director Head of Biostatistics at Target Health, is a subject matter expert in study design and sample size calculations with more than 30 years of industry experience. He has worked in the leading CROs in the industry and has assisted ...
ByStatsol
With the emergence of COVID-19, Decentralisation of Clinical Trials became necessary to comply with social distancing requirements while carrying out clinical research. Over the past few years, the clinical trial landscape has shifted its focus to patient-centric practices to promote patient engagement. But now as the pandemic is long gone, it is time to reflect on how DCT studies are genuinely ...
ByClinion
The Clinical CRISPR Successes Are Stacking Up. But Where’s the Emphasis on Quality Control? In mid-September, Intellia released some promising data on two of their CRISPR-based therapeutics. These results are a significant milestone for genome editing and validation of its effectiveness in the clinic. However, the safety of CRISPR-based therapeutics has been a major concern and part of a ...
When promising drug candidates are identified for further investigation in clinical trials, sponsor companies are usually optimistic about outcomes. But there are times, when after years of sunk effort and resources, clinical trials fail to bring a viable drug to market. Frequently, a drug fails for safety or efficacy reasons that are beyond a sponsor’s control. However, to some degree, ...
The Dana-Farber Cancer Institute utilized SWOT analysis to targeted protein degradation drug development to better evaluate the approach's strengths, weaknesses, opportunities, and threats. SWOT (Strengths-Weaknesses-Opportunities-Threats) analysis is frequently used in business development and strategic planning, but it may also be used to critically analyze quickly evolving fields, as the ...
Published by Vijay K Singh and Thomas M Seed on September 3, 2021, in Expert Opinion on Drug Discovery and deals with the necessity of animal models for modern drug research in the direction of animal strains, animal models, requirements, and pathways for developing new drugs. The use of experimental animal models in drug development aids in the understanding of disease and/or related conditions' ...
Durham, NC (April 28, 2020) - A review article published in PNAS highlights Symberix's efforts to understand the role of the human microbiota in drug efficacy and toxicity. Symberix co-founder Matt Redinbo is featured in the article alongside other leaders from the emerging field of “pharmacomicrobiomics” -- the study of mechanisms behind the microbial impact on drug metabolism. ...
Durham, NC (February 3, 2020) - An article in Nature highlights Symberix's efforts to understand the complex relationship between drugs and the microbiome. The paper discusses recent contributions to the emerging field of “pharmacomicrobiomics” -- the study of how microbes impact drug disposition, efficacy, and toxicity. Symberix is developing bacteria-targeted small molecules that ...